A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza

Trial Profile

A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Zanamivir (Primary) ; Oseltamivir
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ZORO
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2015 Planned End Date changed from 1 Feb 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 27 Jan 2015 Planned primary completion date changed from 1 Feb 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top